TrialNature communications2023

Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial.

Li Yuan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.